|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
31,350,000 |
Market
Cap: |
16.03(M) |
Last
Volume: |
15,038 |
Avg
Vol: |
14,997 |
52
Week Range: |
$0.2127 - $0.648 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Catalyst Biosciences is a research and clinical development biopharmaceutical company. Co.'s complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, improved albumin-fused Complement Factor I (CFI) molecule intended for prophylactic subcutaneous or intravitreal administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential component 3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. Co. has several engineered protease programs in discovery or early non-clinical development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
9,750 |
Total Buy Value |
$0 |
$0 |
$0 |
$4,584 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
60,000 |
60,000 |
60,000 |
60,000 |
Total Sell Value |
$950,777 |
$950,777 |
$950,777 |
$950,777 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
3 |
3 |
3 |
3 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-03 |
4 |
OE |
$5.55 |
$27,917 |
D/D |
5,030 |
6,189 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-02 |
4 |
S |
$30.00 |
$6,000 |
D/D |
(200) |
1,159 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-02 |
4 |
OE |
$5.55 |
$1,110 |
D/D |
200 |
1,359 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-01 |
4 |
S |
$30.16 |
$383,144 |
D/D |
(12,703) |
1,159 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-01 |
4 |
OE |
$5.55 |
$70,502 |
D/D |
12,703 |
13,862 |
|
- |
|
Brennan Jeffrey P |
SVP - Bus. & Commercial Dev. |
|
2011-03-01 |
4 |
S |
$30.00 |
$37,920 |
D/D |
(1,264) |
0 |
|
- |
|
Brennan Jeffrey P |
SVP - Bus. & Commercial Dev. |
|
2011-03-01 |
4 |
OE |
$2.93 |
$3,704 |
D/D |
1,264 |
1,264 |
|
- |
|
Hicks Karen A |
VP Human Resources |
|
2011-03-01 |
4 |
S |
$30.00 |
$37,290 |
D/D |
(1,243) |
0 |
|
- |
|
Hicks Karen A |
VP Human Resources |
|
2011-03-01 |
4 |
OE |
$8.32 |
$10,489 |
D/D |
1,243 |
1,243 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-03-01 |
4 |
S |
$30.00 |
$340,800 |
D/D |
(11,360) |
7,735 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-03-01 |
4 |
OE |
$8.51 |
$96,674 |
D/D |
11,360 |
19,095 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-02-28 |
4 |
S |
$28.00 |
$433,468 |
D/D |
(15,481) |
7,735 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-02-28 |
4 |
OE |
$5.55 |
$85,920 |
D/D |
15,481 |
23,216 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-02-16 |
4 |
AS |
$26.52 |
$441,656 |
D/D |
(16,655) |
7,735 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-02-16 |
4 |
OE |
$1.75 |
$29,146 |
D/D |
16,655 |
24,390 |
|
- |
|
Richard John P |
Director |
|
2011-01-19 |
4 |
S |
$27.11 |
$135,543 |
D/D |
(5,000) |
5,333 |
|
- |
|
Richard John P |
Director |
|
2011-01-19 |
4 |
OE |
$2.71 |
$13,550 |
D/D |
5,000 |
10,333 |
|
- |
|
Bencherif Merouane |
SVP, Preclinical Research |
|
2011-01-19 |
4 |
S |
$27.09 |
$818,257 |
D/D |
(30,203) |
0 |
|
- |
|
Bencherif Merouane |
SVP, Preclinical Research |
|
2011-01-19 |
4 |
OE |
$1.75 |
$83,069 |
D/D |
30,203 |
30,203 |
|
- |
|
Richard John P |
Director |
|
2011-01-18 |
4 |
S |
$27.38 |
$68,440 |
D/D |
(2,500) |
5,333 |
|
- |
|
Richard John P |
Director |
|
2011-01-18 |
4 |
OE |
$2.71 |
$6,775 |
D/D |
2,500 |
7,833 |
|
- |
|
Bencherif Merouane |
SVP, Preclinical Research |
|
2011-01-18 |
4 |
S |
$27.17 |
$619,476 |
D/D |
(22,800) |
0 |
|
- |
|
Bencherif Merouane |
SVP, Preclinical Research |
|
2011-01-18 |
4 |
OE |
$5.55 |
$126,540 |
D/D |
22,800 |
22,800 |
|
- |
|
Hicks Karen A |
VP Human Resources |
|
2011-01-14 |
4 |
S |
$27.50 |
$47,273 |
D/D |
(1,719) |
0 |
|
- |
|
Hicks Karen A |
VP Human Resources |
|
2011-01-14 |
4 |
OE |
$2.93 |
$5,037 |
D/D |
1,719 |
1,719 |
|
- |
|
530 Records found
|
|
Page 9 of 22 |
|
|